The effect of rosemary on cognitive and pulmonary function and daily activity

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 80

Inclusion Criteria

Age between 40 and 80 years
The ratio of FEV1 to FVC is less than 0.7 exhalation pressure volume per second (FEV1)?less than 70% of reference value and increase in FEV1 less than 10% after inhalation of beta-two agonists
Detection of COPD based on grade one to three gold criteria approved by spirometry and physician
Patients with mild to moderate cognitive impairment based on MMSE test with a minimum score of 23
Have a history of smoking at least ten packs of cigarettes a year
At least one year has passed since the diagnosis of COPD in the patient
Do not take any herbal medicine supplements effective in improving cognitive function and lung function and daily activity (such as Ginseng?Thyme?Nigella sativa?Chamomile?etc)from two months ago
No alcohol?hookah and drugs
Do not take antioxidants as a supplement during the last three months(vitamin E?Omega3?a-tocopherol?etc)

Exclusion Criteria

Lack of motivation of the patient to continue cooperation
Hospitalization during the study
Neurological disease?cancer?acute infection and known mental disorders(anxiety?depression and delirium)
Patient deterioration?unstable hemodynamic status?life threatening arrhythmias
Participate in other pulmonary rehabilitation programs or meditation and yoga
Do not take the capsules for two consecutive days
Demonstrate sensitivity to capsules
If the patient needs to take drugs that affect cognitive or pulmonary function or the amount of daily activity (such as muscle relaxants?etc)during the study?in addition to the main treatment drugs?excluded from the study
Patients receiving vasodilators include organic nitrates and people with pulmonary ?hypertension?obstructive sleep apnea?malignancies?gastrointestinal abnormalities?recent surgery?severe endocrine disease?kidney disease?liver disease?inflammatory and infectious disease?and musculoskeletal disease active that causes impairment in exercise and respiratory capacity

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cognitive function. Timepoint: Before starting treatment and one week after completing the 60 day treatment period. Method of measurement: Montreal Cognitive Dysfunction Questionnaire.;Pulmonary function. Timepoint: Before starting treatment and one week after completing the 60 day treatment period. Method of measurement: Spirometry device.;Activity daily of living. Timepoint: Before starting treatment and one week after completing the 60 day treatment period. Method of measurement: Lawton and London Questionnaire.

Secondary Outcome Measures